ArticleCommunications medicine2025
Continuous vital sign monitoring of acute Lassa fever using wearable biosensor devices in West Africa.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Wearable Electronic Monitoring of Vital Signs in Hospitalised Adults: A Nursing Focused Scoping Review of Clinical, Economic and Implementation Outcomes.Journal of advanced nursing · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundLassa fever is a fulminant viral illness associated with high in-hospital mortality. This disease constitutes a serious public health concern in West Africa, in particular Nigeria and the Mano River Union region (Guinea, Liberia, and Sierra Leone). In Sierra Leone, continuous monitoring of critically ill patients is hindered by a lack of equipment and personnel.
methodsWe used wearable biosensor devices to remotely monitor hospitalized individuals with acute Lassa fever in order to describe vital sign trends that may be associated with clinical outcome and to evaluate the feasibility of this approach in a resource-limited setting.
resultsThe case fatality rate among participants (n = 8) was 62.5%, with a median time from hospital presentation to death of 2 days. Our results show that non-survivors (n = 5) spent a greater proportion of their monitoring period in the age-specific tachycardia range (45.8%) compared to survivors (1.7%), and had lower mean heart rate variability (10 ms) compared to those that survived (59 ms). Due to inconsistent sensor adhesion, as well as Bluetooth and cellular connectivity issues, over 80% of collected vital sign data was discarded for poor quality.
conclusionsReal-time monitoring of vital signs using wearable biosensors may have the potential to identify individuals at increased risk for poor outcomes in Lassa fever by detecting age-specific tachycardia and reductions in heart rate variability. Whether this represents an improvement upon traditional bedside vital sign collection in resource-limited settings is not clear, as a substantial proportion of monitoring data was of poor quality. Technical improvements in sensor connectivity and adhesion are needed to enable widespread use of this device, for both clinical and research purposes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.